U.S. Trade Rep’s IP Report: China Always Improving, But Never Enough
This article was originally published in PharmAsia News
Executive Summary
For the past 20 years, the Office of the U.S. Trade Representative has released an annual Special 301 Report on the "adequacy and effectiveness of intellectual property rights protection by U.S. trading partners," and every year it seems to say that despite improvement, China's IP protection system remains a concern
You may also be interested in...
Forced Technology Transfer Hinders Innovation In China – USTR
China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.
Sanofi Asks Thailand To Review Compulsory Licensing Policy
Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).